| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1093/AJCP/111.4.507 |
| P698 | PubMed publication ID | 10191771 |
| P2093 | author name string | Jennette JC | |
| Davies D | |||
| van der Woude F | |||
| Benson E | |||
| Savage CO | |||
| Esnault V | |||
| Falk RJ | |||
| Gillis D | |||
| Hagen EC | |||
| Jayne D | |||
| Paspaliaris B | |||
| Pollock W | |||
| Pusey C | |||
| Savige J | |||
| Silvestrini R | |||
| Wieslander J | |||
| Wiik A | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 507-513 | |
| P577 | publication date | 1999-04-01 | |
| P1433 | published in | American Journal of Clinical Pathology | Q15750224 |
| P1476 | title | International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA) | |
| P478 | volume | 111 |
| Q64075750 | A Case Report of Multiple Myeloma Associated With Myeloperoxidase and Proteinase-3 Antibodies Posing a Diagnostic Dilemma |
| Q86002246 | A fully automated IIF system for the detection of antinuclear antibodies and antineutrophil cytoplasmic antibodies |
| Q55026656 | A phosphatidylinositol 3-kinase inhibitor strongly suppressed pulmonary vascular remodeling of allergic vasculitis in a murine model. |
| Q35593169 | ANCA associated pauci-immune retinal vasculitis |
| Q38062452 | ANCA testing: the current stage and perspectives |
| Q84251050 | ANCA-associated glomerulonephritis/systemic vasculitis in childhood: clinical features-outcome |
| Q98778531 | ANCA-associated vasculitis |
| Q36633133 | Aberrant cytokine pattern of the nasal mucosa in granulomatosis with polyangiitis |
| Q80249706 | Agreement of anti-neutrophil cytoplasmic antibody measurements obtained from serum and plasma |
| Q37673239 | An approach to the diagnosis and management of systemic vasculitis. |
| Q53327076 | Analysis of pulmonary allergic vasculitis with eosinophil infiltration in asthma model of mice. |
| Q43784846 | Analysis of risk epitopes of anti-neutrophil antibody MPO-ANCA in vasculitis in Japanese population |
| Q51579316 | Analytical and diagnostic accuracy of the EliA automated enzyme fluoroimmunoassay for antineutrophil cytoplasmic autoantibody detection. |
| Q45063516 | Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass |
| Q51764280 | Anti-neutrophil cytoplasmic antibodies and their clinical significance. |
| Q34504768 | Antibodies and vascular involvement in inflammatory joint disease: clinical relevance |
| Q39456610 | Antineutrophil antibodies define clinical and genetic subgroups in primary sclerosing cholangitis |
| Q44051499 | Antineutrophil cytoplasmic antibodies (ANCA) and small vessel vasculitis |
| Q43928839 | Antineutrophil cytoplasmic antibodies in Bulgarian patients with rheumatoid arthritis: characterization and clinical associations |
| Q45971399 | Antineutrophil cytoplasmic antibodies in bile are associated with disease activity in primary sclerosing cholangitis. |
| Q40509127 | Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. |
| Q35038822 | Antineutrophil cytoplasmic antibodies testing in a large cohort of unselected greek patients |
| Q36550721 | Antineutrophil cytoplasmic antibodies. |
| Q54560537 | Antineutrophil cytoplasmic antibody (ANCA) testing: Audit from a clinical immunology laboratory. |
| Q40398143 | Antineutrophil cytoplasmic antibody-associated vasculitis with oculomotor nerve palsy |
| Q38016379 | Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up? |
| Q37051208 | Antineutrophil cytoplasmic autoantibodies: how should the biologist manage them? |
| Q34571110 | Antineutrophil cytoplasmic autoantibody in the absence of Wegener's granulomatosis or microscopic polyangiitis: implications for the surgical pathologist |
| Q35395166 | Apolipoprotein H, a new mediator in the inflammatory changes ensuring in jeopardised human myocardium |
| Q34449112 | Are antineutrophil cytoplasmic antibody-associated vasculitides pauci-immune? |
| Q34796025 | Atypical p-ANCA in PSC and AIH: a hint toward a "leaky gut"? |
| Q42019441 | Audit of the clinical usefulness of a rapid qualitative ELISA screen for antimyeloperoxidase and antiproteinase 3 antibodies in the assessment of patients with suspected vasculitis |
| Q38657160 | Autoantibodies and their Judicious Use in Pediatric Rheumatology Practice |
| Q27489093 | Autoantibodies in primary sclerosing cholangitis |
| Q26849664 | Autoantibodies in renal diseases - clinical significance and recent developments in serological detection |
| Q38466778 | Autoantibodies in systemic vasculitis |
| Q24804645 | Autoantibodies in vasculitis |
| Q89835389 | Autoantibody Biomarkers in Rheumatic Diseases |
| Q38268340 | Autoimmune diagnostics: the technology, the strategy and the clinical governance |
| Q36907743 | Automated interpretation of ANCA patterns - a new approach in the serology of ANCA-associated vasculitis. |
| Q36410589 | Automatic reading of ANCA-slides: evaluation of the AKLIDES system |
| Q34477430 | Automation in indirect immunofluorescence testing: a new step in the evolution of the autoimmunology laboratory. |
| Q45743059 | Brief report: prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis. |
| Q36149845 | Case report and review of minocycline-induced cutaneous polyarteritis nodosa |
| Q36208055 | Classification of the vasculitides: are they clinically useful? |
| Q38382986 | Clinical aspects of indirect immunofluorescence for autoimmune diseases |
| Q34395162 | Clinical aspects of primary vasculitis |
| Q37199242 | Clinical immunology review series: an approach to the use of the immunology laboratory in the diagnosis of clinical allergy. |
| Q46745711 | Clinical importance of antineutrophil cytoplasmic antibody positivity during propylthiouracil treatment |
| Q34395174 | Clinical management and treatment of vasculitis |
| Q80505002 | Clinical relevance of anti-PR3 capture ELISA in diagnosing Wegener's granulomatosis |
| Q34449099 | Clinical use of serological tests for antineutrophil cytoplasmic antibodies. What do the studies say? |
| Q35592429 | Clinical utility of ANCA tests for the dermatologist |
| Q34109070 | Clinical value of antineutrophil cytoplasmic antibodies |
| Q51013683 | Comparison of a novel chemiluminescence enzyme immunoassay (CLEIA) with enzyme-linked immunosorbent assay (ELISA) for the determination of MPO-ANCA in patients with ANCA-associated vasculitis. |
| Q85071518 | Contribution of immunofluorescence to identification and characterization of antineutrophil cytoplasmic antibodies in inflammatory bowel disease |
| Q34422614 | Current and emerging techniques for ANCA detection in vasculitis |
| Q28295728 | Cutaneous manifestations of Churg–Strauss syndrome: report of two cases and review of the literature |
| Q53612047 | Cutaneous sarcoid-like granulomas with alveolar hemorrhage and c-ANCA PR-3. |
| Q35743185 | Cutting edge diagnostics in rheumatology: the role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology |
| Q33712321 | Detection rate and antigenic specificities of antineutrophil cytoplasmic antibodies in chinese patients with clinically suspected vasculitis |
| Q38033433 | Diagnosis and management of pulmonary vasculitis |
| Q39716589 | Diagnostic ANCA algorithms in daily clinical practice: evidence, experience, and effectiveness |
| Q84675171 | Diagnostic Approach to ANCA-associated Vasculitides |
| Q34187942 | Diagnostic and pathogenetic role of antineutrophil cytoplasmic autoantibodies |
| Q48113738 | Diagnostic outcome and indications for testing in patients with positive ANCA at a Canadian tertiary care centre |
| Q36577453 | Diagnostic significance of ANCA in vasculitis |
| Q28362587 | Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy |
| Q50879150 | Discrepancies between two immunoassays for the determination of MPO and PR3 autoantibodies. |
| Q47306787 | Do anti-neutrophil cytoplasmic antibodies play a role in systemic lupus erythematosus (SLE) patients? Analysis of the University College Hospital SLE cohort |
| Q37919834 | Does this patient have vasculitis? |
| Q40684657 | EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. |
| Q38388432 | EUROPattern Suite technology for computer-aided immunofluorescence microscopy in autoantibody diagnostics |
| Q34853086 | Effects of imatinib mesylate on pulmonary allergic vasculitis in a murine model |
| Q41958938 | Emergency testing for antineutrophil cytoplasmic antibodies combined with a dialog-based policy between clinician and biologist: effectiveness for the diagnosis of ANCA-associated vasculitis |
| Q27478112 | Epitope mapping of anti-PR3 antibodies using chimeric human/mouse PR3 recombinant proteins |
| Q46568853 | Evaluation of a new fluorescent-enzyme immuno-assay for diagnosis and follow-up of ANCA-associated vasculitis |
| Q37156762 | Evaluation of the combined application of ethanol-fixed and formaldehyde-fixed neutrophil substrates for identifying atypical perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease |
| Q36777464 | Eye manifestations in patients with perinuclear antineutrophil cytoplasmic antibody-associated vasculitis: case series and literature review |
| Q48565963 | Fokko Johannes van der Woude, 1953-2006. |
| Q36234282 | Glomerulonephritis due to antineutrophil cytoplasm antibody-associated vasculitis: an update on approaches to management. |
| Q38287415 | Hypogalactosylation of serum IgG in patients with ANCA-associated systemic vasculitis |
| Q27478109 | IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis |
| Q34514787 | IgG from myeloperoxidase-antineutrophil cytoplasmic antibody-positive patients stimulates greater activation of primed neutrophils than IgG from proteinase 3-antineutrophil cytosplasmic antibody-positive patients |
| Q42173432 | Immunofluorescent patterns produced by antineutrophil cytoplasmic antibodies (ANCA) vary depending on neutrophil substrate and conjugate |
| Q27477862 | Indirect immunofluorescence (IIF) of normal washed peripheral blood cells to demonstrate antineutrophil cytoplasmic antibodies (ANCA) |
| Q90374658 | Induction of hemodialysis with an arteriovenous fistula in a patient with hemophilia A |
| Q52854066 | Is minocycline therapy in acne associated with antineutrophil cytoplasmic antibody positivity? A cross-sectional study. |
| Q55354039 | Laboratory Standard in the Diagnosis and Therapy Monitoring of Autoimmune Disease: Vasculitis. |
| Q37634640 | Laboratory investigation in the diagnosis of vasculitis |
| Q34109097 | Laboratory testing in the evaluation and diagnosis of vasculitis |
| Q84600614 | Laryngopharyngeal reflux mimicking limited wegener granulomatosis |
| Q36865417 | Lingual infarction in Wegener's Granulomatosis: a case report and review of the literature |
| Q36667809 | Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides. |
| Q34395155 | Methods for the detection of anti-neutrophil cytoplasmic antibodies. Recommendations for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results |
| Q40379203 | Microscopic polyangiitis initiated with liver dysfunction, calf pain and fever of unknown origin. |
| Q35923750 | Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis. |
| Q37656828 | Myeloperoxidase-antineutrophil Cytoplasmic Antibodies (MPO-ANCA) and Proteinase 3-ANCA without Immunofluorescent ANCA Found by Routine Clinical Testing. |
| Q80948590 | Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement |
| Q38815813 | Neutrophil Extracellular Traps Contain Selected Antigens of Anti-Neutrophil Cytoplasmic Antibodies |
| Q34397155 | Neutrophil functions of patients with vasculitis related to myeloperoxidase-specific anti-neutrophil antibody |
| Q35172206 | Neutrophil-specific autoantibodies in chronic inflammatory bowel diseases |
| Q90415245 | New concepts in ANCA detection and disease classification in small vessel vasculitis: the role of ANCA antigen specificity |
| Q36505735 | New platform technology for comprehensive serological diagnostics of autoimmune diseases |
| Q38883608 | Next-Generation Autoantibody Testing by Combination of Screening and Confirmation-the CytoBead® Technology. |
| Q40303001 | Nonorgan-specific autoantibodies in HIV-infected patients in the HAART era. |
| Q27000411 | Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies |
| Q81096216 | Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Q34514665 | PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC). |
| Q38946711 | Pathogenesis and treatment of ANCA-associated vasculitis-a role for complement. |
| Q36535223 | Pathogenic role and clinical relevance of antineutrophil cytoplasmic antibodies in vasculitides |
| Q36651184 | Pediatric inflammatory bowel disease with cytoplasmic staining of antineutrophil cytoplasmic antibodies |
| Q92188904 | Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide? |
| Q35396591 | Photodynamic treatment of pooled coumarin plasma for external quality assessment of the prothrombin time |
| Q40041740 | Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. |
| Q58051633 | Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome |
| Q46131896 | Prevalence and clinical significance of antineutrophil cytoplasmic antibody in Graves' patients treated with propylthiouracil |
| Q43546669 | Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. |
| Q40096353 | Prospective monitoring of in vitro produced PR3-ANCA does not improve relapse prediction in granulomatosis with polyangiitis. |
| Q58711278 | Proteinase 3; a potential target in chronic obstructive pulmonary disease and other chronic inflammatory diseases |
| Q47383971 | Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides |
| Q82626057 | Pulmonary vasculitis |
| Q36839521 | Pulmonary-renal syndromes |
| Q36560767 | Quantitation of autoantibodies in systemic autoimmune diseases: clinically useful? |
| Q44419035 | Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis |
| Q43010830 | Rational requesting or rationing testing? |
| Q42046372 | Recombinant Protein to Analyze Autoantibodies to Proteinase 3 in Systemic Vasculitis |
| Q46006970 | Recurrence of Wegener's granulomatosis with de novo intraoral presentation treated successfully with rituximab. |
| Q73503215 | Role of TNFalpha in regulation of myeloperoxidase expression in irradiated HL60 promyelocytic cells |
| Q36119478 | Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases |
| Q50076914 | S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis |
| Q34199391 | Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA. |
| Q40446804 | Simultaneous comprehensive multiplex autoantibody analysis for rapidly progressive glomerulonephritis |
| Q81532434 | Study of the autoantibody profile after the acute phase of Kawasaki disease in a cohort of children from North India |
| Q34569292 | Testing for antineutrophil cytoplasmic antibodies |
| Q35588083 | The Churg Strauss syndrome (allergic granulomatous angiitis): review and update |
| Q90211970 | The Diagnostic and Clinical Utility of Autoantibodies in Systemic Vasculitis |
| Q47107377 | The European Vasculitis Society 2016 Meeting Report |
| Q37778584 | The Pulmonary Vasculitides |
| Q35022552 | The basis of T-cell-mediated immunity to chronic myelogenous leukemia |
| Q42058864 | The binding of proteinase 3 antineutrophil cytoplasmic antibodies (PR3-ANCA) varies in different ELISAs. |
| Q35587408 | The effect of a symptom related "gating policy" on ANCA requests in routine clinical practice |
| Q38512570 | The kidneys and ANCA-associated vasculitis: from pathogenesis to diagnosis |
| Q90003776 | The perspective on standardisation and harmonisation: the viewpoint of the EASI president |
| Q27477909 | The pulmonary physician in critical care * Illustrative case 3: Pulmonary vasculitis |
| Q50044061 | Tuberculosis and pauci-immune crescentic glomerulonephritis |
| Q38497364 | Twenty-eight years with antineutrophil cytoplasmic antibodies (ANCA): how to test for ANCA - evidence-based immunology? |
| Q38389839 | Twenty-five years of European Union collaboration in ANCA-associated vasculitis research |
| Q38243776 | Uncertainty of measurement: an immunology laboratory perspective |
| Q79319641 | Use of ANCA in diagnosis |
| Q38174024 | Utility of immunologic testing in suspected rheumatologic disease |
| Q35909318 | Vaccines in leukemia. |
| Q35555099 | Variations in performance characteristics of commercial enzyme immunoassay kits for detection of antineutrophil cytoplasmic antibodies: what is the optimal cut off? |
| Q37566353 | Vasculitides associated with IgG antineutrophil cytoplasmic autoantibodies in childhood |
| Q36746092 | Vasculitis reminds us that 'Ockham's razor' may still apply in the elderly |
| Q33814342 | Vasculitis--diagnosis and treatment |
| Q34990085 | Vasculitis: Wegener granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis, polyarteritis nodosa, and Takayasu arteritis |
| Q36387577 | Wegener's granulomatosis: a rare, chronic and multisystem disease. |
| Q46857224 | Wegener's granulomatosis: clinical and laboratory results of a university hospital study of 20 patients from Turkey |
| Q51240099 | What to do when you suspect your patient suffers from pulmonary vasculitis? |
| Q24791101 | What you should know about PR3-ANCA. An introduction |
| Q86270688 | [ANCA-associated vasculitis] |
| Q86911314 | [ANCA-associated vasculitis] |
| Q73173867 | [Antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae mannan antibodies: new biological tools for diagnosis of inflammatory bowel disease] |
| Q90793832 | [Chances and Pitfalls of ANA and ANCA Diagnostics] |
| Q81091964 | [Cutaneous vasculitides. A diagnostic approach] |
| Q80148345 | [Laboratory diagnostics of systemic autoimmune diseases. Part II: rheumatoid arthritis and vasculopathies] |
| Q53591253 | [Paradigm shift in ANCA diagnostics : New international consensus recommendations]. |
Search more.